Concepedia

Nikki DeAngelis

ND

4

Publications

212

Citations

4

H-Index

2007

Active since

Affiliations

Janssen (United States)(Current)

Instituto de Investigación Biomédica de Salamanca

The University of Melbourne

University of Bologna

Centro de Investigación del Cáncer

Nikki DeAngelis is an author at Janssen (United States) specializing in cellular biochemistry, chromatin, and gene expression.

Top concepts

MedicineChromatinCell BiologyCell SignalingCell PhysiologyGene ExpressionGene RegulationNatural SciencesMolecular BiologySignal Transduction

Publications per year

2007–2022

4

Publications

4

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva et al. · Blood · 2021 · 131 citations · Full text

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Katja Weisel, Andrew Spencer, Suzanne Lentzsch et al. · Journal of Hematology & Oncology · 2020 · 41 citations · Full text

The High Mobility Group Box Transcription Factor Nhp6Ap Enters the Nucleus by a Calmodulin-dependent, Ran-independent Pathway

John A. Hanover, Dona C. Love, Nikki DeAngelis et al. · Journal of Biological Chemistry · 2007 · 27 citations · Full text

Ran-independent Pathway, Molecular Regulation, Molecular Biology +18

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

Nikki DeAngelis, Catherine Ferrante, Gordon Powers et al. · Cancer Chemotherapy and Pharmacology · 2022 · 13 citations · Full text

Rows per page

1–4 of 4